Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment

Area of Science:

• Nanomedicine
• Oncology
• Drug Delivery Systems

Background:

• Multidrug resistance (MDR) in cancer poses a significant therapeutic challenge.
• Existing treatments often fail due to MDR mechanisms like P-glycoprotein (P-gp) and vacuolar-type ATPase (V-ATPase).
• Targeting the tumor microenvironment offers a novel strategy to overcome MDR.

Purpose of the Study:

• To develop and evaluate a multidrug-resistant nanocracker (MDRC) for treating MDR cancer.
• To investigate the MDRC's ability to target acidic tumor microenvironments and inhibit key MDR mechanisms.
• To assess the therapeutic efficacy and safety of MDRC in preclinical models.

Main Methods:

• Formulation of MDRC as a liposome co-loading pantoprazole (PZ) and paclitaxel (PTX).
• Evaluation of differential drug release kinetics (PZ within 12h, PTX sustained release for 48h).
• Assessment of MDRC's effect on cancer cell uptake, intracellular pH, and cytotoxicity in MDR cancer cell lines (MCF-7/mdr, UV-2237M).
• In vivo studies involving intravenous injection in murine fibrosarcoma models to determine toxicity and therapeutic outcomes.
• Analysis of immune responses, including dendritic cell maturation and cytotoxic T cell activity.

Main Results:

• MDRC demonstrated enhanced cell uptake in P-gp overexpressed MDR cancer cells.
• MDRC significantly increased the cytotoxic efficacy of paclitaxel by modulating intracellular pH.
• Reduced IC50 values were observed for MDRC compared to a simple mixture of PZ and PTX.
• Intravenous administration of MDRC showed no significant systemic toxicity (weight loss, liver dysfunction, organ damage).
• MDRC achieved 80% complete remission in a murine fibrosarcoma model.
• Therapeutic effects were associated with enhanced anti-tumor immunity.

Conclusions:

• MDRC is a promising nanomedicine capable of overcoming multidrug resistance in cancer.
• The formulation effectively targets the acidic tumor microenvironment and inhibits P-gp and V-ATPase.
• MDRC exhibits excellent therapeutic potential with a favorable safety profile.
• The study suggests MDRC could be a transformative therapy for multidrug-resistant tumors.